Clark Abbot F, Brotchie Daniel, Read A Thomas, Hellberg Peggy, English-Wright Sherry, Pang Iok-Hou, Ethier C Ross, Grierson Ian
Glaucoma Research, Alcon Research, Ltd. Fort Worth, Texas 76134, USA.
Cell Motil Cytoskeleton. 2005 Feb;60(2):83-95. doi: 10.1002/cm.20049.
Elevated intraocular pressure is an important risk factor for the development of glaucoma, a leading cause of irreversible blindness. This ocular hypertension is due to increased hydrodynamic resistance to the drainage of aqueous humor through specialized outflow tissues, including the trabecular meshwork (TM) and the endothelial lining of Schlemm's canal. We know that glucocorticoid therapy can cause increased outflow resistance and glaucoma in susceptible individuals, that the cytoskeleton helps regulate aqueous outflow resistance, and that glucocorticoid treatment alters the actin cytoskeleton of cultured TM cells. Our purpose was to characterize the actin cytoskeleton of cells in outflow pathway tissues in situ, to characterize changes in the cytoskeleton due to dexamethasone treatment in situ, and to compare these with changes observed in cell culture. Human ocular anterior segments were perfused with or without 10(-7) M dexamethasone, and F-actin architecture was investigated by confocal laser scanning microscopy. We found that outflow pathway cells contained stress fibers, peripheral actin staining, and occasional actin "tangles." Dexamethasone treatment caused elevated IOP in several eyes and increased overall actin staining, with more actin tangles and the formation of cross-linked actin networks (CLANs). The actin architecture in TM tissues was remarkably similar to that seen in cultured TM cells. Although CLANs have been reported previously in cultured cells, this is the first report of CLANs in tissue. These cytoskeletal changes may be associated with increased aqueous humor outflow resistance after ocular glucocorticoid treatment.
眼压升高是青光眼发生的一个重要危险因素,青光眼是不可逆失明的主要原因。这种高眼压是由于通过包括小梁网(TM)和施莱姆管内皮衬里在内的特殊流出组织排出房水的流体动力学阻力增加所致。我们知道糖皮质激素治疗可导致易感个体的流出阻力增加和青光眼,细胞骨架有助于调节房水流出阻力,并且糖皮质激素治疗会改变培养的TM细胞的肌动蛋白细胞骨架。我们的目的是原位表征流出途径组织中细胞的肌动蛋白细胞骨架,表征地塞米松原位治疗导致的细胞骨架变化,并将这些变化与细胞培养中观察到的变化进行比较。用人眼前节灌注含或不含10(-7)M地塞米松的溶液,并通过共聚焦激光扫描显微镜研究F-肌动蛋白结构。我们发现流出途径细胞含有应力纤维、外周肌动蛋白染色以及偶尔的肌动蛋白“缠结”。地塞米松治疗导致几只眼睛的眼压升高,并增加了整体肌动蛋白染色,出现更多的肌动蛋白缠结和交联肌动蛋白网络(CLANs)的形成。TM组织中的肌动蛋白结构与培养的TM细胞中所见的非常相似。虽然CLANs先前已在培养细胞中报道,但这是首次在组织中报道CLANs。这些细胞骨架变化可能与眼部糖皮质激素治疗后房水流出阻力增加有关。